{"id":"bortezomib-melphalan-prednisone-thalidomide","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Peripheral neuropathy"},{"rate":"40-60","effect":"Thrombocytopenia"},{"rate":"30-50","effect":"Anemia"},{"rate":"20-40","effect":"Infection"},{"rate":"20-40","effect":"Nausea/vomiting"},{"rate":"20-30","effect":"Constipation"},{"rate":"20-40","effect":"Fatigue"},{"rate":"5-15","effect":"Venous thromboembolism"}]},"_chembl":{"chemblId":"CHEMBL325041","moleculeType":"Small molecule","molecularWeight":"384.25"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bortezomib is a proteasome inhibitor that blocks NF-κB signaling and triggers apoptosis in myeloma cells. Melphalan is an alkylating agent causing DNA damage. Prednisone is a corticosteroid with immunosuppressive and anti-inflammatory effects. Thalidomide is an immunomodulatory agent that enhances cereblon-mediated degradation of IKZF1 and IKZF3, promoting anti-myeloma activity. Together, these agents provide synergistic cytotoxic and immunomodulatory effects.","oneSentence":"This combination regimen targets multiple pathways in multiple myeloma by inhibiting proteasome function, inducing DNA damage, suppressing TNF-α, and promoting cereblon-mediated protein degradation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:44:22.594Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma (newly diagnosed or relapsed/refractory)"}]},"trialDetails":[{"nctId":"NCT01998971","phase":"PHASE1","title":"A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-02-18","conditions":"Multiple Myeloma","enrollment":240},{"nctId":"NCT01063179","phase":"PHASE3","title":"Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Fondazione EMN Italy Onlus","startDate":"2006-05","conditions":"Multiple Myeloma","enrollment":511},{"nctId":"NCT00507416","phase":"PHASE3","title":"Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2007-06","conditions":"Multiple Myeloma","enrollment":502},{"nctId":"NCT00652041","phase":"PHASE4","title":"Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2007-01","conditions":"Multiple Myeloma","enrollment":40},{"nctId":"NCT00443235","phase":"PHASE3","title":"GEM05 for Patients With Multiple Myeloma More Than 65 Years Old","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2005-03","conditions":"Multiple Myeloma","enrollment":260},{"nctId":"NCT00461747","phase":"PHASE3","title":"GEM05 for Patients With Multiple Myeloma Under 65 Years","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2006-03","conditions":"Multiple Myeloma","enrollment":390},{"nctId":"NCT00320476","phase":"PHASE2","title":"VTD Followed By MPT Maintenance As a First Line Treatment For The Patients With MM Who Are Non-Transplant Candidates","status":"COMPLETED","sponsor":"Korean Multiple Myeloma Working Party","startDate":"2006-04","conditions":"Multiple Myeloma","enrollment":35},{"nctId":"NCT00358020","phase":"PHASE2","title":"Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients","status":"COMPLETED","sponsor":"University of Turin, Italy","startDate":"2004-11","conditions":"Multiple Myeloma","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Bortezomib","Velcade","Thalidomide"],"phase":"phase_3","status":"active","brandName":"Bortezomib, Melphalan, Prednisone, Thalidomide","genericName":"Bortezomib, Melphalan, Prednisone, Thalidomide","companyName":"Fondazione EMN Italy Onlus","companyId":"fondazione-emn-italy-onlus","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination regimen targets multiple pathways in multiple myeloma by inhibiting proteasome function, inducing DNA damage, suppressing TNF-α, and promoting cereblon-mediated protein degradation. Used for Multiple myeloma (newly diagnosed or relapsed/refractory).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}